Introduction
Myocardial ischemia-reperfusion injury often occurs after acute myocardial infarction thrombolysis, PTCA and coronary artery bypass grafting or other treatments. The mechanism of the injury is a patho-physiology phenomena caused by the expression of cytokines, especially the surface adhesion molecules [1] , which can start and induce the aggregation and adhesion of inflammatory cells and cause immune injury of tissue cell. It seriously affects the treatment efficacy and prognosis of patients with myocardial infarction. Peroxisome proliferators-activated receptor (PPAR) is a member of nuclear receptor superfamily.
Retinoic acid, degenerate prime, thyroid hormone, vitamin D, and orphan receptors are also members of the nuclear receptor superfamily [2] . PPAR 毭 is mainly expressed in adipose tissues and the immune system, which closely related to the adipocyte differentiation, insulin resistance and body immune [3] .
Through activating nuclear receptors PPAR 毭 , rosiglitazone can regulate the production and transportation of the glucose, and also regulate the transcription of the insulin response genes. And rosiglitazone can relieve ischemiareperfusion myocardial injury by some physiological effects such as inhibiting the inflammation, improving the endothelial function and reducing the oxidative stress [4, 5] .
In this study we investigated the protective effect of rosiglitazone on myocardial ischemia-reperfusion injury and its mechanism. We expect to provide new ideas for the clinical treatment of myocardial ischemia-reperfusion, thus more patients can be benefit from it.
Objective: To explore mechanism and protective effect of rosiglitazone on myocardial ischemia reperfusion (I/R) injury. 
Materials and methods

Animal
Male Japanese long-ear white rabbits, ( 
Establishment of myocardial ischemia-reperfusion injury models in rabbits
Healthy male Japanese white big-ear rabbits were under anesthesia with urethane (20%, 1 g/kg). Animals were then bound to a plate with the back side down and chest shearing. A skin incision was made from the sternoclavicular joint line to the point above the xiphoid process along the sternum midline. The 2nd, 3rd, 4th ribs were cut in the left sternal margin, stretched with a thoracic incision, then the pericardium was opened to expose the heart. A small round looper stab 2 mm below the left bundel of coronary artery was hold by needle holder with the 2/T line for ligation.
Grouping and administration
A total of 48 rabbits were randomly divided into four groups: (1) Sham operation group: Coronary artery was only exposed but not ligated. Rabbits were fed with common pellet feedstuff for 3 days; (2) Ischemia-reperfusion group: ligated for 30 min, under reperfusion for 60 min. The rabbits were feed with common pellet feedstuff for 3 days; (3) Low dose rosiglitazone group: ligated for 30 min, under reperfusion for 60 min. Rabbits were fed with common pellet feedstuff for 3 days and rosglitazone 0.5 mg/kg/day; (4) High dose rosiglitazone group: ligated for 30 min, under reperfusion for 60 min. Rabbits were fed with common pellet feedstuff for 3 days and rosglitazone 3 mg/kg/day. Successful ligation was confirmed by significantly ascending ST-segment of ECG in the ischemia-reperfusion group, low dose rosiglitazone group and high dose rosiglitazone group after operation. After reperfusion for 60 min, common carotid artery blood was added with heparin anticoagulant tube for biochemical testing.
Indexes measurement
Plasmic level of myocardial enzymes plasma serum (CTn 栺, CK-MB), high-sensitivity C-reactive protein (hsCRP) were measured in carotid arterial blood under anticoagulation. The blood was centrifuged at 2 500 rpm for 10mins, and then the supernatant was collected to determine plasma SOD, MDA, GSH-PX, NO and ET. The hearts were harvested, then were rinsed with PBS buffer. The ischemic area of the heart were cut into approximately 1 mm in parallel, and were placed in 1% TTC or 0.25% NBT phosphate buffer (pH=7.4), 37℃,under water bath for 30 min. The dyed and undyed areas were isolated under dissecting microscope. The infarcted myocardium was pale and the none-infarcted myocardium was blue. The BI2000 image analysis system was used to calculate the percentage of the infarcted myocardium area accounted for the total ventricular area.
Isolated hearts were washed with stationary liquid. The left ventricular anterior myocardial tissues were cut into strips, and then placed in stationary liquid for 2 h, followed by rinsed with 0.09 mmol KH 2 PO 4 for 15 min, and stored in this solution. It was dehydrated in ascending series of ethanol, cleared in xylene, embedded in paraffin, and stained by HE staining. Then the structural c myocardial pathological change was observed under light microscope.
Statistical analysis
The experimental data were analyzed with SPSS17.0 statistical software. All measurement data were expressed with mean依SD. And single-factor analysis of variance (ANOVA) was applied in the comparison among many groups, q-test was used to compare between two groups. P <0.05 indicated statistical significance. Comparatively describing method was used to analyze the pathomorphological data.
Results
Effect on cardiac enzymes (CTn 栺 , CK-MB) content and hsCRP content in plasma
The results showed that compared with the sham group,the CTn 栺 , CK-MB, and hsCRP levels in plasma were significantly increased in the ischemia-reperfusion group. And compared with the ischemia-reperfusion group,the CTn 栺 , CK-MB, hsCRP levels in plasma in the high dose rosiglitazone group and the low-dose rosiglitazone group were decreased significantly (Table 1) . 
Effect on NO, ET and GSH-Px content in plasma
The results showed that compared with the sham group, the NO, GSH-Px levels in plasma were significantly decreased in the ischemia-reperfusion group, while ET levels increased. Compared with the ischemia-reperfusion group, the NO, ET, GSH-Px levels in plasma in the high dose rosiglitazone group and the low-dose rosiglitazone group were increased significantly, while ET levels decreased significantly. The content of NO, ET, GSH-Px in plasma had no significant difference between rosiglitazone high dose group and rosiglitazone low dose group (Table 2) . 
Effect on T-SOD and MDA content in plasma
The results showed that compared with the sham group, the MDA levels in plasma were significantly increased in the ischemia-reperfusion group, and the T-SOD was significantly decreased. Compared with the ischemiareperfusion group, the MDA levels in plasma in the high dose rosiglitazone group and the low-dose rosiglitazone group were decreased significantly, while the T-SOD was increased significantly (Table 3) . 
Myocardial infarct size
As compared with sham-operated group [(19.2依5.5%)], the myocardial infarct size of the ischemia-reperfusion group [(41.3依8.5)%] was significantly increased (P <0.05). Compared with the ischemic reperfusion group, the myocardial infarct size of the low-dose rosiglitazone group [(26.5依7.1)%] and the high-dose rosiglitazone group [(23.4依6.6)%] were significantly decreased (P<0.05). Compared with the sham group, the rosiglitazone low-dose group and the rosiglitazone high-dose group showed no significant difference (P> 0. 05).
Pathological structures under light microscopy
Myocardial fibers arranged in neat rows in the sham group under the light microscope, without inflammatory cell infiltration of the myocardial interstitial. Group I/R were of swelling and disorder myocardial fibers, inflammatory cells and even focal necrosis in the myocardial interstitial. Myocardial cell nuclei in high and low dose rosiglitazone groups were in uniform size, myocardial fibers were mild swelled, and there were fibroblasts and inflammatory cell infiltration at different degrees.
Discussion
Acute myocardial infarction is the leading disease threatening the human life and health at present, while myocardial ischemia -reperfusion can cause irreversible damage,death and apoptosis to the damaged myocardial cells, thus aggravate myocardial damage and increase mortality [6] . Myocardial ischemia reperfusion injury is a process which was participated by a variety of inflammatory cell nucleus inflammatory cytokines. Neutrophils, monocytes, mast cells, and macrophages all play important roles in this process, while TNF-毩, IL-1, IL-6, IL-8 were also involved in the reperfusion injury [7] .
PPAR-毭 is expressed in many immune cells, and PPAR-毭 ligand 15d-PGJ2 can regulate many immune responses.
With the presence of PPAR-毭 , 15d-PGJ2 at very low concentrations can inhibit the transcriptional effects which is mediated by LPS, active protein 21, NF-毷 B, and the signal TRANSDUCER and activator of transcription 1 [8] . With the interactions with NF-毷 B protein, PPAR-毭 can prevent the binding of NF-毷 B with the inflammatory cytokines gene promoter region homologous cis element [9] . PPAR [11, 12] and produce the anti-inflammatory effect. The key to the activation of T lymphocyte is to control the early differentiation of IL-2 gene expression of the lymphocyte reaction. The activation of PPAR-毭 can inhibit the gene expression of IL-2, thus can inhibit the early activation of T lymphocytes and shows anti inflammatory effect.
The experiment showed that the pretreatment of PPAR-毭 receptor rosiglitazone on myocardial ischemia-reperfusion model can significantly increase the concentration of SOD, GSH-PX, NO, and also reduced the concentration of plasma serum CK-MB cTNI, hsCRP, MDA and ET. It can significantly reduce the incidence of arrhythmia and reduce the size of myocardial infarction. Rosiglitazone can protect myocardial mitochondrial function of rats and maintain mitochondrial ultrastructural integrity. From the results of the experiment we can speculate that rosiglitazone pretreatment can protect myocardial and reduce ischemiareperfusion injury. However, the specific mechanism is still unclear. Studies have shown that as PPAR-毭 receptor agonist, rosiglitazone can affect the formation and activation of inflammatory cells and inflammatory cytokines, inhibit the expression of MCP-1, intercellular adhesion molecule and inducible oxide synthase by regulating the expression of PPAR-毭 [13, 14] . In addition, Khandoudi et al [15] found that by inhibiting Jun N-terminal kinase phosphorylation and inhibit activated protein-1 DNA binding activity, TZDs can inhibit the damage of myocardial ischemia and improve the function of heart. Rosiglitazone can improve myocardial ischemia-reperfusion injury by inhibiting inflammation, improving endothelial function and reducing the generation of oxygen free radicals. The specific mechanism is the content of our further study.
